Literature DB >> 9270638

Preoperative chemotherapy versus surgical therapy alone for squamous cell carcinoma of the esophagus: a prospective randomized trial.

S Law1, M Fok, S Chow, K M Chu, J Wong.   

Abstract

OBJECTIVE: This study investigated the role of preoperative chemotherapy in squamous cell cancer of the esophagus.
METHODS: A prospective randomized trial was undertaken in 147 patients: 74 received preoperative chemotherapy comprising cisplatin and 5-fluorouracil and 73 had surgical therapy alone. End points were cancer and therapy-related deaths.
RESULTS: Sixty-six patients (89%) in the chemotherapy group underwent resection compared with 69 (95%) in the control group (p = not significant). Of the 60 patients who had resection after completing the chemotherapy program, 35 (58%) had a significant response, of whom four (6.7%) had a complete pathologic response. Postoperative mortality rates were 8.3% and 8.7% in the chemotherapy and control groups, respectively (p = not significant). Significant downstaging was evident with chemotherapy; curative resections were possible in 67% of these patients compared with 35% in the control group (p = 0.0003). T3 and T4 tumors were found in 67% and 91% of the chemotherapy and control groups, respectively (p = 0.0002). The respective figures for N1 disease were 70% and 88% (p = 0.009). An intent-to-treat analysis of survival showed no significant difference between the two groups. Median survivals were 16.8 and 13 months, respectively (p = 0.17). Of those who completed the chemotherapy and resection, responders fared better than control patients. Median survivals were 42.2 months and 13.8 months, respectively (p = 0.003). Median survival (8.3 months) was worse for nonresponders than for control patients (p = 0.03). The recurrence pattern suggested a significant reduction in locoregional disease with chemotherapy.
CONCLUSIONS: Preoperative chemotherapy was safe and resulted in significant downstaging and an increased likelihood of curative resection. Survival was not better than that in the surgery-alone group, but responders did fare better than nonresponders.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9270638     DOI: 10.1016/S0022-5223(97)70147-8

Source DB:  PubMed          Journal:  J Thorac Cardiovasc Surg        ISSN: 0022-5223            Impact factor:   5.209


  90 in total

1.  Preoperative chemotherapy for advanced esophageal cancer and relation with histological effect.

Authors:  Y Hosoya; H Shibusawa; H Nagai; I Ueno; K Sakuma; T Nagashima; N Kobayashi; K Kanazawa
Journal:  Surg Today       Date:  1999       Impact factor: 2.549

2.  Analysis of postoperative complications after esophagectomy for esophageal cancer in patients receiving neoadjuvant therapy.

Authors:  R Eguchi; H Ide; T Nakamura; K Hayashi; M Ohta; F Okamoto; H Itoh; K Takasaki
Journal:  Jpn J Thorac Cardiovasc Surg       Date:  1999-11

3.  [No improvement of prognosis by neoadjuvant chemotherapy alone in operable esophageal carcinoma].

Authors:  R Fietkau
Journal:  Strahlenther Onkol       Date:  1999-05       Impact factor: 3.621

Review 4.  Neoadjuvant treatment of esophageal cancer.

Authors:  Nicholas P Campbell; Victoria M Villaflor
Journal:  World J Gastroenterol       Date:  2010-08-14       Impact factor: 5.742

5.  [Neoadjuvant therapy for squamous cell carcinoma of the esophagus].

Authors:  F Lordick
Journal:  Chirurg       Date:  2005-11       Impact factor: 0.955

6.  Surgical management of esophageal carcinoma.

Authors:  Amit N Patel; John T Preskitt; Joseph A Kuhn; Robert F Hebeler; Richard E Wood; Harold C Urschel
Journal:  Proc (Bayl Univ Med Cent)       Date:  2003-07

Review 7.  Current management of esophageal cancer.

Authors:  Simon Law; John Wong
Journal:  J Gastrointest Surg       Date:  2005-02       Impact factor: 3.452

Review 8.  [18F-FDG-PET in therapy response of esophageal cancer].

Authors:  H A Wieder; K Herrmann; K Ott; B J Krause
Journal:  Radiologe       Date:  2007-02       Impact factor: 0.635

9.  Influence of incomplete neoadjuvant chemotherapy on esophageal carcinoma.

Authors:  Yushi Fujiwara; Shigeru Lee; Satoru Kishida; Ryoya Hashiba; Ken Gyobu; Ryoko Naka; Masaki Nishiyama; Toshio Ihara; Masashi Takemura; Harushi Osugi
Journal:  Int J Clin Oncol       Date:  2018-05-11       Impact factor: 3.402

10.  Apparent diffusion coefficient modifications in assessing gastro-oesophageal cancer response to neoadjuvant treatment: comparison with tumour regression grade at histology.

Authors:  Francesco De Cobelli; Francesco Giganti; Elena Orsenigo; Michaela Cellina; Antonio Esposito; Giulia Agostini; Luca Albarello; Elena Mazza; Alessandro Ambrosi; Carlo Socci; Carlo Staudacher; Alessandro Del Maschio
Journal:  Eur Radiol       Date:  2013-04-16       Impact factor: 5.315

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.